Submit your Abstract
Monday, 15 January 2024, 23:59 CET
Submission deadline
Submit your Abstract
Elevate your professional profile as a recognised expert in your specialised area of knowledge. Prepare and submit your abstract now.
ESOC 2024 provides you with the ideal platform to showcase your regular abstract or late breaking abstract onsite in Basel. Authors interested in submitting an abstract for ESOC 2024 have the option to choose from a diverse range of topics.
Prepare your abstract submission
Clinical Trial Definition
A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions (such as novel drugs, specific devices, behavioural therapy etc.) on health-related biomedical or behavioural outcomes).
When submitting a clinical trial, please always indicate the trial registration number (e.g., clinicaltrials.gov NO).
Ongoing Trials Topic
Is only for proposed posters that will describe the design and/or progress of an ongoing trial – i.e., trials that will not have closed in time to present results at ESOC 2024.
Studies Excluding Clinical Trials
Is for all studies which do NOT qualify as clinical trial as defined above.
Placeholder Abstract
How to proceed:
Late Breaking Science:
Guidelines for the preparation of abstracts
Please carefully read the below Guidelines for the preparation of your abstract.
Notification
Each abstract will be reviewed and rated by at least 4 external blinded experts and final selection will be made by the Scientific Programme Committee. Notification of acceptance or rejection of submitted abstracts will be sent to the corresponding authors via email by mid-March 2024. Full instructions concerning preparation and presentation will be included and will be made available on the conference website.
Publication
ESOC 2024 has an embargo policy on all abstracts submitted to the conference. The embargo will be lifted on 15 May 2024. All accepted abstracts will be published in the peer-reviewed journal.
Questions?
If you have questions regarding abstracts technical questions or need assistance, contact the abstract team at ESOC.Abstracts@congrex.com including/referring to the name of the congress.
Abstract hotline: +41 61 686 77 22 (Monday – Friday during business hours)
Travel Grants:
Young Investigator Award:
This is a focused workshop for early career investigators.
The aim of this workshop is to support young stroke researchers in promoting their proposed or ongoing research project to the ESOC audience. They will be given the opportunity to present their work and receive feedback from an expert mentor. The goal of this feedback is to allow young researchers to optimise their study design.
As in previous years, young investigators (≤35 years) will be invited to submit an abstract for the workshop describing their research project, preferably a project still under development or interim results from an ongoing project. Abstracts can be submitted to ESOC as a special category ( “4.30 YSPR – Study Design Workshop”).
The successful applicants will give an oral presentation, followed by constructive assessment of the study’s design and advice on its future development by a senior, internationally renowned invited investigator. In addition to providing expert guidance on the development of the study, the workshop will be an opportunity for the young researchers to promote their work to the wider community and establish collaborations.
The presenters of the two top scoring abstracts will receive a place at the ESO Summer School or the ESO Edinburgh Stroke Winter School in 2024. All presenters will be interviewed by other Young Stroke Physicians and Researchers and the interviews will be featured on the ESO blog.
1,00 |
Clinical Trials |
1,01 | ACUTE MANAGEMENT – NEITHER THROMBOLYSIS NOR THROMBECTOMY |
1,02 | ACUTE MANAGEMENT – THROMBOLYSIS OR THROMBECTOMY |
1,03 | PREVENTION |
1,04 | REHABILITATION & RECOVERY |
2,00 |
Placeholder Late Breaking Trials (Results available at the conference) |
2,01 | PLACEHOLDER – NEITHER THROMBOLYSIS NOR THROMBECTOMY |
2,02 | PLACEHOLDER – THROMBOLYSIS OR THROMBECTOMY |
2,03 | PLACEHOLDER – PREVENTION |
2,04 | PLACEHOLDER – REHABILITATION & RECOVERY |
3,00 |
ONGOING TRIALS (Poster only, results are NOT available at the conference) |
3,01 | ONGOING TRIALS |
4,00 |
STUDIES – EXCLUDING TRIALS |
4,01 | HYPERACUTE MANAGEMENT – EXCLUDING CLINICAL TRIAL RESULTS |
4,02 | THROMBOLYSIS – EXCLUDING CLINICAL TRIAL RESULTS |
4,03 | NEUROINTERVENTION – EXCLUDING CLINICAL TRIAL RESULTS |
4,04 | SECONDARY PREVENTION – EXCLUDING CLINICAL TRIAL RESULTS |
4,05 | REHABILITATION – EXCLUDING CLINICAL TRIAL RESULTS |
4,06 | EPIDEMIOLOGY & RISK FACTORS |
4,07 | IMAGING – HYPERACUTE |
4,08 | IMAGING – NON ACUTE |
4,09 | DIAGNOSIS/INVESTIGATION OF STROKE ETIOLOGY |
4,10 | PROGNOSIS AND OUTCOME AFTER STROKE |
4,11 | STROKE COMPLICATIONS |
4,12 | CEREBROVASCULAR MANIFESTATIONS OF INFECTIONS |
4,13 | ATHEROSCLEROSIS |
4,14 | RARE CAUSES including dissection |
4,15 | STROKE IN THE YOUNG (INCLUDING PAEDIATRIC STROKE) |
4,16 | CARDIOEMBOLISM & HEART-BRAIN INTERACTIONS |
4,17 | INTRACEREBRAL HAEMORRHAGE |
4,18 | SAH, ANEURYSMS AND VASCULAR MALFORMATIONS |
4,19 | COGNITION AND VASCULAR COGNITIVE IMPAIRMENT |
4,02 | SMALL VESSEL DISEASE |
4,21 | SEX, GENDER AND STROKE |
4,22 | PATHOPHYSIOLOGY OF STROKE / TRANSLATIONAL MEDICINE |
4,23 | GENETICS, ‘OMICS AND BIOMARKERS |
4,24 | CLINICAL PRACTICE, MANAGEMENT AND CARE |
4,25 | PRE-HOSPITAL SERVICE ORGANISATION |
4,26 | SERVICE ORGANISATION incl. quality improvement |
4,27 | BRAIN REORGANISATION AND RECOVERY |
4,28 | TECHNOLOGY INNOVATIONS: ROBOTS, VIRTUAL REALITY, ARTIFICIAL INTELLIGENCE AND MORE |
4,29 | CASE REPORTS |
4,30 | YSPR – Study Design Workshop |
You might also be interested in